PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe

PolyPid to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales ADVANZ PHARMA to receive exclusive rights to commercialize D-PLEX 100 for the prevention of surgical site infections in abdominal and cardiac surgeries in Europe , leveraging its